Depot goserelin and danazol pre-treatment before rollerball endometrial ablation for menorrhagia.
OBJECTIVE
To compare the safety and efficacy of a GnRH agonist, depot goserelin, and danazol as preoperative treatments before rollerball endometrial ablation.


METHODS
We performed an open, randomized study of women with clinically convincing histories of menorrhagia. Two treatment groups of equal size (goserelin acetate, 3.6 mg subcutaneous implant given monthly, n = 30; and danazol, 200 mg two times per day, n = 30) were treated for 2 months before undergoing endometrial ablation, which entailed using the rollerball with 80-100 watts of coagulating current.


RESULTS
Measured menstrual blood loss decreased dramatically after ablation, with 74% of goserelin users and 62% of danazol users achieving complete amenorrhea by the end of the 6-month follow-up period. Among women who did not achieve complete amenorrhea, those in the danazol group were more likely to experience occasional episodes of moderate or heavy bleeding. Mean measured blood loss decreased from 94.8 to 1.1 mL at 3 months and 1.0 mL at 6 months after goserelin, and 97.9 to 15.0 mL and 7.4 mL after danazol. Menstrual pain also improved markedly. The median duration of surgery was 20 minutes (range 5-55) in both groups, median irrigation fluid deficit was 100 mL (range 0-800), and median operative blood loss was 20 mL (range 1-50). Endometrium was less than 2 mm thick in all goserelin and most danazol users. Side effects of goserelin and danazol therapy were all within the expected pattern for these drugs.


CONCLUSIONS
Depot goserelin and danazol both provide adequate endometrial preparation before rollerball endometrial ablation for treatment of menorrhagia due to ovulatory dysfunctional uterine bleeding.
Fraser
I S
IS
Department of Obstetrics and Gynaecology, University of Sydney, Australia.
Healy
D L
DL
Torode
H
H
Song
J Y
JY
Mamers
P
P
Wilde
F
F
D003131:Combined Modality Therapy; D003613:Danazol / Q000008:administration & dosage* / Q000009:adverse effects; D003692:Delayed-Action Preparations; D004717:Endometrium / Q000601:surgery*; D004965:Estrogen Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D017273:Goserelin / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D017075:Laser Coagulation; D008595:Menorrhagia / Q000503:physiopathology / Q000628:therapy*; D011300:Preoperative Care
D003692:Delayed-Action Preparations; D004965:Estrogen Antagonists; D017273:Goserelin; D003613:Danazol